Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 223, pseudogene" (RNU6-223P) is classified as a **pseudogene** of the U6 small nuclear RNA (snRNA) gene family. U6 snRNA is a highly conserved non-coding RNA that is a component of the spliceosome complex, essential for pre-mRNA splicing in eukaryotes[1][2]. However, a *pseudogene* like RNU6-223P typically does not produce a functional product and is not known to play a direct biological role nor serve as a receptor, enzyme, or therapeutic target. Multiple copies and pseudogenes of the U6 snRNA gene exist in the human genome as evolutionary byproducts, but the functional U6 snRNA itself is central to the splicing reaction and RNA processing[2]. Pseudogenes generally do not exhibit known disease associations, are not used as biomarkers, and are not targeted by drugs. **Notes on correctness**: - This target is marked as *incorrect* for inclusion as a molecular target, since RNU6-223P is a non-functional pseudogene rather than a protein, receptor, or RNA species with therapeutic relevance. - The canonical target U6 snRNA is called “RNA, U6 small nuclear” (or just "U6 snRNA"), but the specific pseudogene (223) has no known biological or therapeutic significance[2]. - U6 snRNA itself is not a therapeutic target, but rather a key RNA molecule in the spliceosome machinery[1][2]. - No known molecular function, disease involvement, or drug interactions are attributed to this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 223, pseudogene (RNU6-223P).